• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

目前用于治疗单纯疱疹病毒 1 型和 2 型感染的药物。

Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.

机构信息

Towson University Herpes Virus Lab, Department of Biological Sciences, Towson University, Towson, MD 21252, USA.

Towson University Department of Chemistry, Towson, MD 21252, USA.

出版信息

Viruses. 2021 Jun 25;13(7):1228. doi: 10.3390/v13071228.

DOI:10.3390/v13071228
PMID:34202050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8310346/
Abstract

Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaherpesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses.

摘要

单纯疱疹病毒-1 和 -2(HSV-1 和 -2)是引起全球感染的三种人类α疱疹病毒中的两种。由于这两种病毒在没有明显迹象和症状的情况下也可以被感染,而且仍然会导致终身感染,因此我们必须采取干预措施来控制它们,尤其是在免疫功能低下的患者中。虽然有许多实验性疫苗正在考虑中,但目前的干预措施仅包括抗病毒化学治疗药物。这篇综述探讨了所有经临床批准用于预防这些病毒反复发作的最坏后果的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/64fc91037a0f/viruses-13-01228-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/17f5b26ba861/viruses-13-01228-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/4a1ddd7c6af8/viruses-13-01228-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/324eea9fd116/viruses-13-01228-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/fea36f68ee64/viruses-13-01228-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/99d950d3b830/viruses-13-01228-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/64fc91037a0f/viruses-13-01228-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/17f5b26ba861/viruses-13-01228-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/4a1ddd7c6af8/viruses-13-01228-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/324eea9fd116/viruses-13-01228-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/fea36f68ee64/viruses-13-01228-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/99d950d3b830/viruses-13-01228-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13cc/8310346/64fc91037a0f/viruses-13-01228-g006.jpg

相似文献

1
Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.目前用于治疗单纯疱疹病毒 1 型和 2 型感染的药物。
Viruses. 2021 Jun 25;13(7):1228. doi: 10.3390/v13071228.
2
Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.单纯疱疹病毒对核苷类似物的耐药性:机制、流行率和管理。
Antimicrob Agents Chemother. 2011 Feb;55(2):459-72. doi: 10.1128/AAC.00615-10. Epub 2010 Nov 15.
3
Novel targets for the development of anti-herpes compounds.抗疱疹化合物开发的新靶点。
Infect Disord Drug Targets. 2007 Mar;7(1):11-8. doi: 10.2174/187152607780090766.
4
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.疱疹病毒感染的早期步骤被蛋白酶体抑制剂阻断。
mBio. 2019 May 14;10(3):e00732-19. doi: 10.1128/mBio.00732-19.
5
The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.抗人类免疫缺陷病毒药物替诺福韦,一种逆转录酶抑制剂,也靶向单纯疱疹病毒 DNA 聚合酶。
J Infect Dis. 2018 Feb 14;217(5):790-801. doi: 10.1093/infdis/jix605.
6
Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.从一般免疫功能正常人群和获得性免疫缺陷综合征患者中分离出的阿昔洛韦耐药单纯疱疹病毒的频率。
Int J Dermatol. 2007 Dec;46(12):1263-6. doi: 10.1111/j.1365-4632.2007.03449.x.
7
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).使用(S)-1-(3-羟基-2-膦酰甲氧基丙基)胞嘧啶(HPMPC)成功治疗由对阿昔洛韦和膦甲酸钠耐药的单纯疱疹病毒引起的进行性黏膜皮肤感染。
Clin Infect Dis. 1994 Apr;18(4):570-8. doi: 10.1093/clinids/18.4.570.
8
2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.2-[4,5-二氟-2-(2-氟苯甲酰氨基)-苯甲酰氨基]苯甲酸,一种具有抗疱疹病毒 1 型和 2 型耐药分离株活性的抗病毒化合物。
Antimicrob Agents Chemother. 2012 Nov;56(11):5735-43. doi: 10.1128/AAC.01072-12. Epub 2012 Aug 20.
9
Management of oral herpes simplex virus infections: The problem of resistance. A narrative review.口腔单纯疱疹病毒感染的管理:耐药性问题。一篇叙述性综述。
Oral Dis. 2024 Apr;30(3):877-894. doi: 10.1111/odi.14635. Epub 2023 Jun 6.
10
Photodynamic Inactivation of Herpes Simplex Viruses.光动力失活单纯疱疹病毒。
Viruses. 2018 Sep 29;10(10):532. doi: 10.3390/v10100532.

引用本文的文献

1
The Procaine-Based ProcCluster Impedes the Second Envelopment Process of Herpes Simplex Virus Type 1.基于普鲁卡因的ProcCluster阻碍单纯疱疹病毒1型的第二次包膜化过程。
Int J Mol Sci. 2025 Jul 25;26(15):7185. doi: 10.3390/ijms26157185.
2
Applying CRISPR Technologies for the Treatment of Human Herpesvirus Infections: A Scoping Review.应用CRISPR技术治疗人类疱疹病毒感染:一项范围综述。
Pathogens. 2025 Jul 1;14(7):654. doi: 10.3390/pathogens14070654.
3
Elephant Cathelicidin-Derived Peptides Inhibit Herpes Simplex Virus 1 Infection.

本文引用的文献

1
Novel Insights to Enhance Therapeutics With Acyclovir in the Management of Herpes Simplex Encephalitis.新型见解:增强阿昔洛韦在单纯疱疹脑炎治疗中的疗效。
J Pharm Sci. 2021 Apr;110(4):1557-1571. doi: 10.1016/j.xphs.2021.01.003. Epub 2021 Jan 13.
2
Lipophilic Triphosphate Prodrugs of Various Nucleoside Analogues.各种核苷类似物的亲脂性三磷酸前药。
J Med Chem. 2020 Jul 9;63(13):6991-7007. doi: 10.1021/acs.jmedchem.0c00358. Epub 2020 Jun 29.
3
Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster.
源自大象cathelicidin的肽抑制单纯疱疹病毒1感染。
Antibiotics (Basel). 2025 Jun 28;14(7):655. doi: 10.3390/antibiotics14070655.
4
New Benzimidazole 3'-Deoxynucleosides: Synthesis and Antiherpes Virus Properties.新型苯并咪唑3'-脱氧核苷:合成及其抗疱疹病毒特性
Biomolecules. 2025 Jun 23;15(7):922. doi: 10.3390/biom15070922.
5
Aryl hydrocarbon receptor facilitates HSV-1 lytic infection by enhancing viral gene transcription and receptor expression.芳烃受体通过增强病毒基因转录和受体表达促进单纯疱疹病毒1型的裂解感染。
Front Cell Infect Microbiol. 2025 Jun 25;15:1548038. doi: 10.3389/fcimb.2025.1548038. eCollection 2025.
6
Activation of cryptic biosynthetic pathways in Saccharopolyspora spinosa through deletion of the spinosyn gene cluster: induction of cryptic and bioactive natural products.通过删除多杀菌素基因簇激活多刺糖多孢菌中隐蔽生物合成途径:隐蔽且具有生物活性的天然产物的诱导
Arch Pharm Res. 2025 Jun 17. doi: 10.1007/s12272-025-01553-1.
7
Global research trend of Herpes simplex keratitis: a bibliometric analysis and visualization from 1941 to 2024.单纯疱疹性角膜炎的全球研究趋势:1941年至2024年的文献计量分析与可视化
Front Med (Lausanne). 2025 Mar 19;12:1526116. doi: 10.3389/fmed.2025.1526116. eCollection 2025.
8
Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.卵巢癌中的溶瘤病毒:我们目前的进展如何?一篇叙述性综述。
Pathogens. 2025 Feb 3;14(2):140. doi: 10.3390/pathogens14020140.
9
Next-generation sequencing and immuno-informatics for designing a multi-epitope vaccine against HSV-1-induced uveitis.用于设计抗单纯疱疹病毒1型诱导性葡萄膜炎的多表位疫苗的新一代测序和免疫信息学
Front Immunol. 2025 Jan 31;16:1461725. doi: 10.3389/fimmu.2025.1461725. eCollection 2025.
10
Anti-HSV-1 agents: an update.抗单纯疱疹病毒1型药物:最新进展
Front Pharmacol. 2025 Jan 21;15:1451083. doi: 10.3389/fphar.2024.1451083. eCollection 2024.
药品和医疗器械局批准摘要:阿美替尼用于治疗带状疱疹。
J Dermatol. 2020 Jul;47(7):683-688. doi: 10.1111/1346-8138.15393. Epub 2020 May 18.
4
Chemistry and anti-herpes simplex virus type 1 evaluation of 4-substituted-1H-1,2,3-triazole-nitroxyl-linked hybrids.4-取代-1H-1,2,3-三唑-氮氧自由基连接的杂化物的化学性质和抗单纯疱疹病毒 1 型评估。
Mol Divers. 2021 Nov;25(4):2035-2043. doi: 10.1007/s11030-020-10094-2. Epub 2020 May 6.
5
Antiviral Drugs and Acute Kidney Injury (AKI).抗病毒药物与急性肾损伤(AKI)
Infect Disord Drug Targets. 2019;19(4):375-382. doi: 10.2174/1871526519666190617154137.
6
Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial.按需口服替诺福韦/恩曲他滨暴露前预防对男男性行为者单纯疱疹病毒1/2发病率的影响:ANRS IPERGAY试验的一项子研究
Open Forum Infect Dis. 2018 Nov 8;5(11):ofy295. doi: 10.1093/ofid/ofy295. eCollection 2018 Nov.
7
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺:用于治疗 HIV-1 感染的药物。
Drugs. 2018 Nov;78(17):1817-1828. doi: 10.1007/s40265-018-1010-7.
8
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.一项随机、双盲、安慰剂对照的 3 期临床试验,评估口服溴昔洛韦在异基因造血细胞移植中用于巨细胞病毒预防的效果。
Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381. doi: 10.1016/j.bbmt.2018.09.038. Epub 2018 Oct 4.
9
Antiviral Drugs Against Alphaherpesvirus.抗α疱疹病毒药物。
Adv Exp Med Biol. 2018;1045:103-122. doi: 10.1007/978-981-10-7230-7_6.
10
Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.926例接受核苷(酸)类似物治疗的慢性乙型肝炎病毒学突破患者的临床特征分析
Eur J Intern Med. 2018 Jul;53:e9-e10. doi: 10.1016/j.ejim.2018.02.014. Epub 2018 May 24.